# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹86 Cr** consolidated Q2 FY'26 (+118%) · **₹110 Cr** H1 FY'26 (+120%) * **Gross Margin:** **₹25 Cr** Q2 (28%) · **₹35 Cr** H1 (30%) * EBITDA: ₹19 Cr Q2 (21%) · ₹30.5 Cr H1 (25%) * **PAT:** **₹14 Cr** Q2 (16%) · **₹19 Cr** H1 (16%) ## B. Revenue Growth * **Explosive Top-Line Momentum:** Revenue growth reflects strong market adoption and post-merger operating scale, with **H1 sales doubling year-on-year**. ## C. Gross & EBITDA Margins * **Margin Expansion Accelerates:** EBITDA margin improved sharply to 21% in Q2, driven by **operating leverage** and cost discipline following prior-year investment phase. * **Gross Margin Uplift:** Sustained improvement in gross margin to 30% in H1, indicating favorable pricing and production efficiency. ## D. PAT & Profit Leverage * **Profit Surge Outpaces Revenue:** Bottom-line growth significantly exceeded top-line, with **PAT in H1 increasing over 100x YoY**, highlighting operating leverage and structural cost benefits. * **High-Margin Mix Contribution:** Profitability gains amplified by rising contribution from **export sales** and **preventive healthcare solutions**. ## E. Balance Sheet Strength * **Robust Financial Position:** Company maintains a strong liquidity buffer with **net cash of ₹28 Cr** and a conservative capital structure (**debt/equity: 0.04**), enabling strategic flexibility. --- # 2. Product & Segment Performance ## A. Key Figures * **Total Income Growth:** **>120% YoY** (quarterly) * **Revenue Mix:** **70% India** · **30% Overseas** ## B. Imaging Systems Performance * **Indigenous Leadership:** Positioned as a pioneer in locally manufactured MRI and diagnostic technologies, leveraging policy support and cost-efficient, sustainable solutions for Tier-2/3 markets. * **Strategic Expansion:** Radiology business stable in FY ’25; expanding from diagnostic MRIs into interventional MRI and CT imaging via Time Medical (TMIV). * **Dual Revenue Model:** Prefers **outright sales** as an OEM but maintains a lease-based option; operations focused on domestic market with majority revenue from India. ## C. Preventive Healthcare Growth * **Primary Growth Driver:** Preventive Healthcare fueled the >120% YoY income surge, contributing **over half** of performance through early screening, wellness, and contactless diagnostics. * **Platform-Led Strategy:** Operating as an integrated ecosystem—combining AI, cloud, and analytics—with initiatives like **Flynn OncoCare** and **NTB TB platform** aligned with WHO and Ayushman Bharat. * **Recurring Revenue Model:** Emphasizes **subscription-based** per-screening payments, offering shorter sales cycles and sustainable, repetitive business; confirmed by management. * **School Health Kiosk Initiative:** Version 1 rollout planned for Q3–Q4; business model (subscription vs. sale) under evaluation, with prior indication of **₹1 Cr** potential. ## D. Diagnostic Segment Trends * **Market Tailwinds:** Diagnostic imaging growth driven by urbanization, non-communicable disease prevalence, and public-private investment in Tier-2/3 MRI/CT expansion. * **Strategic Parity:** Equal focus on **Radiology and Diagnostic** segments, with continued emphasis on shifting from disease care to early detection and digital, patient-centric delivery. --- # 3. Order Book & Demand ## A. Key Figures * **Global Diagnostic Imaging Market:** **$45–50 Bn** (2024) → **~$70 Bn** by 2030 (5–6% CAGR) * **Global MRI Market:** **$11–12 Bn** (growing at 8–9% CAGR), with **Asia-Pacific** as primary growth driver * **India MRI TAM:** **~500 units/year** (15% CAGR), with demand projected to exceed **1,000 units/year** in 3–4 years * **Export Revenue Mix:** **5–10%** (prior year) → **increasing traction**, signaling international expansion ## B. MRI Sales Backlog * **Extended Sales Cycle:** Radiology equipment deployments follow a **6 to 12-month cycle**, particularly for large-scale MRI orders. * **Strong Backlog Visibility:** Management confirms robust order book momentum, especially in the MRI segment, supporting near-term revenue visibility. * **Market Share Ambition:** Targeting **15–20% share** of addressable market, underpinned by current order pipeline and execution confidence. ## C. Export Market Traction * **Strategic International Expansion:** Shift from domestic focus to growing export footprint, leveraging demand in **Asia-Pacific, Middle East, and Africa**. * **Policy Tailwinds:** Government-backed **import substitution** and **public-private partnerships** enhance competitiveness in cost-sensitive markets. * **Regional Growth Leadership:** Asia-Pacific emerges as fastest-growing region for imaging, driven by healthcare investments in **India, Indonesia, Philippines, and China**. ## D. Government-Driven Demand * **Structural Demand Catalysts:** National programs like **Ayushman Bharat**, **National Health Mission**, and new **tertiary hospital MRI mandates** are scaling imaging infrastructure. * **Cancer & TB Initiatives Boost Imaging Use:** Expansion of oncology networks and AI-enabled TB screening drives adoption of diagnostic imaging and digital tools. * **Lease Model Adoption:** MOU with **Sikkim Government** for MRI installations reflects flexible deployment strategies aligned with public sector needs. --- # 4. Capacity & Manufacturing ## A. Key Figures * **MRI Production Capacity:** **80 units/year** single shift · scalable to **150–160 units/year** with two shifts ## B. MRI Production Capacity * **Make-in-India Milestone:** FMV launched the **first and only accredited indigenous MRI system**, produced at its Andhra Pradesh MedTech Zone facility, advancing India’s medical technology self-reliance. * **Scalable Output:** Current capacity allows for meaningful volume ramp-up via shift expansion, providing operational flexibility without immediate capital outlay. ## C. Facility Expansion Plans * **Strategic Diversification:** Plans underway to expand facilities for entry into the **CT imaging market**, leveraging existing capacity headroom and strategic readiness. * **Non-Manufacturing Scale-Up:** Expansion for preventive health focuses on **AI, server infrastructure, and personnel**, indicating a tech-enabled service growth model. * **Future-Ready Capacity:** Ability to pursue **brownfield or greenfield expansions** remains intact for long-term demand capture, though no committed timelines disclosed. ## D. Cost Efficiency vs Competitors * **Significant Capex Advantage:** Fischer MRI systems offer **20–35% lower capital expenditure** versus global peers (GE, Philips, Siemens), enhancing affordability for diagnostic centers. * **Lower Total Cost of Ownership:** Combined with **10–15% lower operating expenses**, Fischer’s systems deliver compelling cost-efficiency, strengthening competitive positioning. --- # 5. Technology & Innovation ## A. AI & Cloud Integration * **Headline:** Fischer advances AI-driven MedTech ecosystem through FlynnCare, integrating **AI diagnostics, teleradiology, and indigenous manufacturing** to enhance accessibility and cost-efficiency in emerging markets. * **Headline:** Core growth fueled by **AI/ML integration**, **portable imaging**, and rising demand for **early disease detection**, aligning with global shift toward affordable, scalable, cloud-connected preventive care solutions. * **Headline:** Firm positioned as **deep tech MedTech innovator** with dual expertise in **medical hardware** and **software-as-a-medical-device**, enabling differentiated, integrated offerings. ## B. Portable & Interop MRI * **Headline:** MICA and QUIN 5 Tesla MRI systems achieve parity with leading OEMs in performance while offering **zero helium dependency, lower power use, and reduced maintenance**—key competitive advantages. * **Headline:** PICA open MRI delivers **high clinical clarity and low operating costs** via cryogenic-free, patient-centric design focused on musculoskeletal and spine imaging. * **Headline:** iMRI platform enables **real-time intraoperative imaging** using **AI, augmented reality, and exoscope technology**, enhancing surgical precision and safety during tumor resection. * **Headline:** Strategic push into **interop MRIs** for integration within operating theatres supports real-time surgical guidance and expands clinical utility. ## C. R&D Pipeline Progress * **Headline:** Pipeline includes development of **CT systems** and advancement of **AI-enabled iMRI** under the DRIS-iMRI Medharanya program with Dr. Iype Cherian to transform neurosurgery. * **Headline:** R&D and commercial teams operate in parallel to ensure **sustained innovation** and **scalable product rollouts** across next-gen platforms. * **Headline:** **Nanomedic skin technology** in pilot phase at select Indian hospitals; **full launch contingent on CDSCO approval**. --- # 6. Regulatory & Market Access Risks ## A. Regulatory Positioning & Competitive Gap * **Strategic Regulatory Advantage:** FMV occupies a unique market position as domestic competitors face technology, debt, and certification challenges, while the company navigates a complex approval pathway for its novel device. * **CDSCO Approval Status:** Device currently under test license in India as a **first-of-its-kind product with no predicate**, with formal application filed under **MD 26 and 27**; full clearance remains pending. * **Global vs. Domestic Divergence:** Nanomedic device is **CE-approved and commercially deployed in Europe**, highlighting a disconnect between international readiness and delayed Indian regulatory adoption. ## B. Export & Market Expansion Constraints * **Domestic Focus Due to Approval Asymmetry:** Commercial strategy remains India-centric due to **completed domestic regulatory approvals**, while global expansion is constrained by **country-specific certification requirements**. * **Export Headwinds:** International growth slowed by **complex supply chain logistics and incremental regulatory applications**, despite operating in markets where high-end global players face cost and infrastructure barriers. --- # 7. Guidance & Outlook ## A. Key Figures * **Sector Growth Outlook:** **15% to 20%** annual growth projected for Indian Medtech sector * **Revenue Mix Target:** **Equal split** between Imaging and Preventive Healthcare segments within 2–3 years ## B. Sector Growth Alignment * **Growth Benchmarking:** Company expects performance to track with the broader Indian Medtech sector’s **15% to 20%** growth trajectory, despite absence of specific financial guidance. * **Strategic Mission:** Focus on enabling early diagnosis to improve patient outcomes and reduce long-term healthcare costs, underpinning growth rationale. ## C. Revenue Mix Projections * **Portfolio Balancing:** Targeting a balanced revenue model with **equal contribution** from Imaging and Preventive Healthcare, signaling strategic shift toward proactive care.